Evaluation of Safety and Efficacy of Intravenous Zanamivir in the Treatment of Hospitalized Japanese Patients with Influenza: An Open-Label,Single-Arm Study

Abstract

Background

Zanamivir is a neuraminidase (NA) inhibitor used for the treatment of influenza. There is an unmet need for a parenteral influenza antiviral therapy to treat hospitalized patients. Therefore the safety and efficacy profile of intravenous zanamivir (IVZ) was examined in Japanese patients with severe influenza.

Methods

The primary objective of this study was to evaluate the safety of IVZ in Japanese patients. Clinical outcome and virological data were also assessed as secondary measures. Patients hospitalized with influenza were treated with IVZ 600 mg twice daily for five days.

Results

A total of 21 subjects received IVZ; 17 subjects (81%) were infected with influenza A/H3N2 and 3 (14%) were infected with influenza B. One subject was not laboratory confirmed influenza-positive. Thirteen subjects received the first dose of IVZ within two days of the onset of influenza symptoms and six subjects had been treated with prior influenza antiviral therapy. Overall adverse events (AEs) and serious adverse events (SAEs) were reported in 13 (62%) and 4 (19%) subjects, respectively. There were no patterns of AEs or SAEs. Median time to clinical response and time to virological improvement were approximately 4 days (range 0.5–22) and 3 days (range 2–5), respectively.

Conclusions

In this study there were no new significant safety findings or patterns of AEs related to IVZ and therefore the safety profile was confirmed for a small sample of Japanese hospitalized patients with influenza. In addition, improvements in clinical and virological measures suggestive of the clinical usefulness were also observed. ClinicalTrials.gov NCT01527110; GSK NAI115215.

References

Department of Health and Human Services. HHS pandemic influenza plan. 2005. (Accessed December 2012.) Available from http://www.flu.gov/planning-preparedness/federal/hhspandemicinfluenzaplan.pdf.

World Health Organization.

Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus.

Wkly Epidemiol Rec 2009; 84: 481–484.

Webster

R.G.

, Govorkova

E.A.

H5N1 influenza - continuing evolution and spread.

N Engl J Med 2006; 355: 2174–2177.

National Institute of Infectious Diseases. Risk assessment and management of cases of human infection with avian influenza A(H7N9) virus in China. (Accessed April 18 2013.) Available from http://www.nih.go.jp/niid/en/flu-m/flutoppage/2276-flu2013h7n9/a-h7n9-niid/3487-riskassess-130418-en.html.

Chen

, Yuan

, Gao

Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study.

Lancet 2014; 383: 714–721.

Lackenby

, Hungnes

, Dudman

S.G.

Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

Euro Surveill 2008; 13: 8026.

Baranovich

, Saito

, Suzuki

Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.

J Clin Virol 2010; 47: 23–28.

Tamiflu^® (oseltamivir phosphate). Package insert 2013. Genentech USA, Inc., South San Francisco, CA, USA.

Watanabe

, Chang

S.C.

, Kim

M.J.

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial.

Clin Infect Dis 2010; 51: 1167–1175.

10.

Sugaya

, Kohno

, Ishibashi

Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.

Antimicrob Agents Chemother 2012; 56: 369–377.

11.

Collins

P.J.

, Haire

L.F.

, Lin

Y.P.

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.

Nature 2008; 453: 1258–1261.

12.

Cockcroft

D.W.

, Gault

M.H.

Prediction of creatinine clearance from serum creatinine.

Nephron 1976; 16: 31–41.

13.

Joy

M.S.

, Matzke

G.R.

, Armstrong

D.K.

A primer on continuous renal replacement therapy for critically ill patients.

Ann Pharmacother 1998; 32: 362–375.

14.

National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004. (Accessed February 2013.) Available from http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/daidsaegradingtable.pdf.

15.

Nguyen

H.T.

, Fry

A.M.

, Gubareva

L.V.

Neuraminidase Inhibitor resistance in influenza viruses and laboratory testing methods.

Antivir Ther 2012; 17: 159–173.

16.

Tisdale

Influenza M2 ion-channel and neuraminidase inhibitors. In Mayers

D.L.

(editor). Antimicrobial drug resistance: mechanisms of drug resistance. New York: Humana Press 2009; pp. 421–447.

17.

CDC. Report May 5, 2009 Interim Guidance for Clinicians on Identifying and Caring for Patients with Swine-origin Influenza A (H1N1) Virus Infection. (Accessed 29 April 2009.) Available from http://idsc.nih.go.jp/disease/swine_influenza/2009cdc/CDC_guidance.html.

18.

CDC. Hospitalized patients with novel influenza A (H1N1) virus infection – California, April–May, 2009. Morbidity and Mortality Weekly Report (MMWR) Vol 58/May 22, 2009. (Accessed 22 May 2009.) Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58e0518a1.htm.

19.

Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood

F.S.

, Jain

Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

N Engl J Med 2009; 360: 2605–2615.

20.

Novel Influenza Countermeasures Committee, Japanese Association for Infectious Diseases. Urgent Proposal by the Japanese Association for Infectious Diseases ‘Indication for use of anti-influenza agents. Revised edition.’ February 28, 2011. Japanese. (Accessed 28 February 2011.) Available from http://www.kansensho.or.jp/influenza/110301soiv_teigen.html.

21.

Marty

F.M.

, Man

C.Y.

, van der Horst

Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, Phase II study.

J Infect Dis 2014; 209: 542–550.

22.

McKimm-Breschkin

, Trivedi

, Hampson

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Antimicrob Agents Chemother 2003; 47: 2264–2272.

23.

Puzelli

, Facchini

, Di Martino

Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.

Antiviral Res 2011; 90: 205–212.

24.

Barnett

J.M.

, Cadman

, Burrell

F.M.

In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.

Virology 1999; 265: 286–295.

25.

Gor

, Cadman

, Dempsey

Antiviral efficacy and sequence analysis of the HA and NA genes of influenza isolates from zanamivir Phase II/III clinical efficacy trials. 39th ICAAC. 26–29 September 1999, San Francisco, CA, USA. Abstract/Poster 284.